Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis

BACKGROUND: Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10–15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable f...

Descripción completa

Detalles Bibliográficos
Autores principales: Craig-Schapiro, Rebecca, Kuhn, Max, Xiong, Chengjie, Pickering, Eve H., Liu, Jingxia, Misko, Thomas P., Perrin, Richard J., Bales, Kelly R., Soares, Holly, Fagan, Anne M., Holtzman, David M.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079734/
https://www.ncbi.nlm.nih.gov/pubmed/21526197
http://dx.doi.org/10.1371/journal.pone.0018850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079734/
https://www.ncbi.nlm.nih.gov/pubmed/21526197
http://dx.doi.org/10.1371/journal.pone.0018850

Ejemplares similares